AI for Science Creates Demand for Lab Infrastructure
A 36氪 人工智能 analysis says OpenAI’s reported acquisition of Orchestra Bio and Anthropic’s disclosed acquisition of Mithril Medicine show model companies moving into biomedical R&D workflows. It identifies three infrastructure opportunities: AI-assisted contract research organizations for experimental validation, laboratory operating systems for automating workflows and scheduling, and scientific-data platforms that preserve experimental context. The report cites Adaptyv, Automata and Transfyr as examples. It also notes that a Google DeepMind and MIT FutureTech survey of 637 US and UK researchers found nearly 50% use AI daily and about 41% are burdened by a backlog of unvalidated hypotheses.
The analysis links faster AI-assisted hypothesis and candidate generation to increased needs for experimental validation, laboratory automation and trustworthy records of how experiments were performed.
今年10月,OpenAI宣布收购Orchestra Bio,一家帮助生物医药团队协调研发任务、管理项目进度的公司。同月,Anthropic披露,已于7月收购Mithril Medicine。两家头部模型公司不约而同买买买。
Mithril的故事显得有些传奇。被收购前,公司只有一名全职员工。创始人借助Claude协调11家外部实验室,处理合同、安排实验、分析数据,推进两类罕见肌营养不良症的药物研究。
一名科学家、一个AI助手,加上一张外部实验室网络,正在探索过去需要更大团队才能承担的研发工作。这也让一个问题变得具体:当AI帮助小团队推进更多研究项目,谁来承接随之增加的实验、执行和数据需求?
换句话说,AI for Science中,“卖铲子”的机会在哪里?
2026年,Google DeepMind与MIT FutureTech发布《AI in Science: Early Insights》,描绘了AI进入科研流程的早期图景。
接受调研的637名英美科研人员中,近50%每天使用AI;约41%因积攒了许多尚未验证的假设头疼。
#OpenAI#Orchestra Bio#Anthropic#Mithril Medicine#Claude#Google DeepMind#MIT FutureTech#Adaptyv#Automata#Medra#Transfyr#Dash Bio